Evidence map›Paper›PMID 25885581›Full record

ArticleMalaria journal2015

Improving uptake and use of malaria rapid diagnostic tests in the context of artemisinin drug resistance containment in eastern Myanmar: an evaluation of incentive schemes among informal private healthcare providers.

Tin Aung, Christopher White, Dominic Montagu, Willi McFarland, Thaung Hlaing, Hnin Su Su Khin, Aung Kyaw San, Christina Briegleb, Ingrid Chen, May Sudhinaraset

Abstract read
In one paragraph

Article in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. CanPathogens and global health · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tin AungPopulation Services International, Yangon, Myanmar. taung@psimyanmar.org.
Christopher WhiteBill and Melinda Gates Foundation, Seattle, USA. Chris.White@gatesfoundation.org.
Dominic MontaguGlobal Health Sciences, University of California, San Francisco, CA, USA. Dominic.Montagu@ucsf.edu.
Willi McFarlandGlobal Health Sciences, University of California, San Francisco, CA, USA. willi_mcfarland@hotmail.com.
Thaung HlaingDepartment of Health, National Malaria Control Programme, Yangon, Myanmar. thlaing@psimyanmar.org.
Hnin Su Su KhinPopulation Services International, Yangon, Myanmar. hsskhin@psimyanmar.org.
Aung Kyaw SanPopulation Services International, Yangon, Myanmar. aksan@psimyanmar.org.
Christina BrieglebGlobal Health Sciences, University of California, San Francisco, CA, USA. chbriegleb@gmail.com.
Ingrid ChenGlobal Health Sciences, University of California, San Francisco, CA, USA. Ingrid.Chen@ucsf.edu.
May SudhinarasetGlobal Health Sciences, University of California, San Francisco, CA, USA. May.Sudhinaraset@ucsf.edu.

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundAs efforts to contain artemisinin resistance and eliminate Plasmodium falciparum intensify, the accurate diagnosis and prompt effective treatment of malaria are increasingly needed in Myanmar and the Greater Mekong Sub-region (GMS). Rapid diagnostic tests (RDTs) have been shown to be safe, feasible, and effective at promoting appropriate treatment for suspected malaria, which are of particular importance to drug resistance containment. The informal private sector is often the first point of care for fever cases in malaria endemic areas across Myanmar and the GMS, but there is little published information about informal private provider practices, quality of service provision, or potential to contribute to malaria control and elimination efforts. This study tested different incentives to increase RDT use and improve the quality of care among informal private healthcare providers in Myanmar.

methodsThe study randomized six townships in the Mon and Shan states of rural Myanmar into three intervention arms: 1) RDT price subsidies, 2) price subsidies with product-related financial incentives, and 3) price subsidies with intensified information, education and counselling (IEC). The study assessed the uptake of RDT use in the communities by cross-sectional surveys of 3,150 households at baseline and six months post-intervention (6,400 households total, 832 fever cases). The study also used mystery clients among 171 providers to assess quality of service provision across intervention arms.

resultsThe pilot intervention trained over 600 informal private healthcare providers. The study found a price subsidy with intensified IEC, resulted in the highest uptake of RDTs in the community, as compared to subsidies alone or merchandise-related financial incentives. Moreover, intensified IEC led to improvements in the quality of care, with mystery client surveys showing almost double the number of correct treatment following diagnostic test results as compared to a simple subsidy.

conclusionsResults show that training and quality supervision of informal private healthcare providers can result in improved demand for, and appropriate use of RDTs in drug resistance containment areas in eastern Myanmar. Future studies should assess the sustainability of such interventions and the scale and level of intensity required over time as public sector service provision expands.

Indexed as

Drug ResistanceMalariaReagent Kits, DiagnosticAntimalarialsArtemisininsFemaleHealth PersonnelHumansMaleMiddle AgedMyanmarParasitologyPrivate PracticeReimbursement, IncentiveAntimalarialsartemisininArtemisininsReagent Kits, Diagnostic

Identifiers

PMID25885581
PMCPMC4355503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.